NeoRx Corp. believes that it already has taken steps to rectify problems that led to suspension last week of a Phase III trial of its skeletal targeted radiotherapy (STR) after severe side effects were detected months after treatment in a Phase I/II trial in multiple myeloma.

In particular, NERX hopes that limiting the exposure of the bladder to radiation from STR, an intravenous radiolabeled bone-targeting small molecule, will prevent additional delayed toxicity from the treatment.